Gout and the Heart

Rheumatic Disease Clinics of North America

Volumn 40, Issue 1, 2014, Pages 125-143

  Bhole, Vidula ^a   Krishnan, Eswar ^b  

^a Stanford University ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Coronary; Gout; Mortality; Risk cardiovascular; Uric acid

Indexed keywords

ALLOPURINOL; COLCHICINE; PLACEBO; PROBENECID; URIC ACID;

CARDIOVASCULAR DISEASE; CASE STUDY; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GOUT; HUMAN; INCIDENCE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; URIC ACID BLOOD LEVEL;

CORONARY; GOUT; MORTALITY; RISK CARDIOVASCULAR; URIC ACID;

CARDIOVASCULAR DISEASES; GOUT; HEART FAILURE; HUMANS; RISK FACTORS;

EID: 84888179287     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.10.004     Document Type: Review

References (54)

1. Wu X., Muzny D.M., Lee C.C., et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. JMol Evol 1992, 34(1):78-84.
2. Ames B.N., Cathcart R., Schwiers E., et al. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981, 78(11):6858-6862.
3. Krishnan E., Baker J.F., Furst D.E., et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54(8):2688-2696.
4. 2) on the renal handling of urate. Metabolism 1986, 35(4):343-348.
5. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63(10):3136-3141.
6. Bhole V., de Vera M., Rahman M.M., et al. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum 2010, 62(4):1069-1076.
7. Huchard H. Traite Clinique des Maladies du Coeur et de L'Aorta 1899, G. Doin, Paris. 3rd edition.
8. Roberts W. Gout. Asystem of medicine by many writers 1897, 160. Macmillan, London. T. Allbutt (Ed.).
9. D'Agostino RB, Kannel WB. Epidemiological background and design: the Framingham Study. Proceedings of the American Statistical Association sesquicentennial invited paper sessions. 1989. p. 707-18.
10. Abbott R.D., Brand F.N., Kannel W.B., et al. Gout and coronary heart disease: the Framingham Study. JClin Epidemiol 1988, 41(3):237-242.
11. Yü T.A., Talbott J.H. Changing trends of mortality in gout. Semin Arthritis Rheum 1980, 10(1):1-9. Elsevier.
12. Nishioka K., Mikanagi K. Aretrospective study on the cause of death, in Japan, of patients with gout. Ryumachi 1981, 21:29.
13. Chen S.Y., Chen C.L., Shen M.L. Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study. Clin Rheumatol 2007, 26(3):308-313.
14. Stamp L.K., Wells J.E., Pitama S., et al. Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities. Intern Med J 2013, 43(6):678-684.
15. Winnard D., Wright C., Jackson G., et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. NZ Med J 2011, 126(1368):53-64.
16. De Muckadell O.B., Gyntelberg F. Occurrence of gout in Copenhagen males aged 40-59. Int J Epidemiol 1976, 5(2):153-158.
17. Gelber A.C., Klag M.J., Mead L.A., et al. Gout and risk for subsequent coronary heart disease: the Meharry-Hopkins study. Arch Intern Med 1997, 157(13):1436.
18. Krishnan E., Svendsen K., Neaton J.D., et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008, 168(10):1104.
19. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116(8):894-900.
20. De Vera M.A., Rahman M.M., Bhole V., et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 2010, 69(6):1162-1164.
21. Teng G.G., Ang L.W., Saag K.G., et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 2012, 71(6):924-928.
22. Kuo C.F., See L.C., Luo S.F., et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010, 49(1):141-146.
23. Kok V.C., Horng J.T., Lin H.L., et al. Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. BMC Cardiovasc Disord 2012, 12(1):108.
24. Stack A., Hanley A., Casserly L., et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013, 106(7):647-658.
25. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009, 2(6):556-562.
26. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003, 107(15):1991-1997.
27. Zhu Y., Pandya B.J., Choi H.K. Comorbidities of gout and hyperuricemia in the US General Population: NHANES 2007-2008. Am J Med 2012, 125(7):679-687.e1.
28. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012, 2(1):e000282.
29. Struthers A., Donnan P., Lindsay P., et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002, 87(3):229-234.
30. Thanassoulis G., Brophy J.M., Richard H., et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010, 170(15):1358.
31. Farquharson C.A., Butler R., Hill A., et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106(2):221-226.
32. George J., Carr E., Davies J., et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006, 114(23):2508-2516.
33. Noman A., Ang D.S., Ogston S., et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010, 375(9732):2161-2167.
34. Goicoechea M., de Vinuesa S.G., Verdalles U., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5(8):1388-1393.
35. Nidorf S.M., Eikelboom J.W., Budgeon C.A., et al. Low-dose colchicine for secondary prevention of cardiovascular disease. JAm Coll Cardiol 2013, 61(4):404-410.
36. Kim S.Y., Guevara J.P., Kim K.M., et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010, 62(2):170-180.
37. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352(16):1685-1695.
38. Epstein F.H., Ross R. Atherosclerosis-an inflammatory disease. NEngl J Med 1999, 340(2):115-126.
39. Solomon D.H., Karlson E.W., Rimm E.B., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107(9):1303-1307.
40. Han C., Robinson D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. JRheumatol 2006, 33(11):2167-2172.
41. Meek I.L., Picavet H.S.J., Vonkeman H.E., et al. Increased cardiovascular risk factors in different rheumatic diseases compared with the general population. Rheumatology 2013, 52(1):210-216.
42. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology 2010, 49(7):1229-1238.
43. Kramer H.M., Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J kidney Dis 2002, 40(1):37-42.
44. Arromdee E., Michet C.J., Crowson C.S., et al. Epidemiology of gout: is the incidence rising?. JRheumatol 2002, 29(11):2403-2406.
45. Mikuls T.R., Saag K.G. New insights into gout epidemiology. Curr Opin Rheumatol 2006, 18(2):199-203.
46. Harris C.M., Lloyd D.C., Lewis J. The prevalence and prophylaxis of gout in England. JClin Epidemiol 1995, 48(9):1153-1158.
47. Klemp P., Stansfield S.A., Castle B., et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997, 56(1):22-26.
48. Kim K.Y., Ralph Schumacher H., Hunsche E., et al. Aliterature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25(6):1593-1617.
49. Zeng Q.Y., Chen R., Darmawan J., et al. Rheumatic diseases in China. Arthritis Res Ther 2008, 10(1):R17.
50. Chuang S.Y., Lee S.C., Hsieh Y.T., et al. Trends in hyperuricemia and gout prevalence: nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr 2011, 20(2):301-308.
51. Darlington L., Slack J., Scott J. Vascular mortality in patients with gout and in their families. Ann Rheum Dis 1983, 42(3):270-273.
52. Janssens H., Van de Lisdonk E., Bor H., et al. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 2003, 20(4):413-416.
53. Cohen S.D., Kimmel P.L., Neff R., et al. Association of incident gout and mortality in dialysis patients. JAm Soc Nephrol 2008, 19(11):2204-2210.
54. Kuo C.F., Yu K.H., See L.C., et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology 2013, 52(1):111-117.